1. Home
  2. YJ vs APM Comparison

YJ vs APM Comparison

Compare YJ & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

N/A

Current Price

$1.73

Market Cap

9.1M

ML Signal

N/A

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.81

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YJ
APM
Founded
2015
2010
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.3M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
YJ
APM
Price
$1.73
$0.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.3K
244.3K
Earning Date
03-27-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$0.65
52 Week High
$2.67
$4.47

Technical Indicators

Market Signals
Indicator
YJ
APM
Relative Strength Index (RSI) 52.85 44.62
Support Level $1.62 $0.74
Resistance Level $1.89 $0.98
Average True Range (ATR) 0.11 0.17
MACD 0.02 -0.01
Stochastic Oscillator 81.71 8.52

Price Performance

Historical Comparison
YJ
APM

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: